NASDAQ:ITCI

Intra-Cellular Therapies (ITCI) Stock Forecast, Price & News

$52.49

+0.40 (+0.77%)

(As of 10/2/2023 ET)

Compare

Today's Range: $51.67
▼
$52.75
50-Day Range: $52.09
▼
$61.96
52-Week Range: $42.01
▼
$67.05

Volume: 766,258 shs
Average Volume: 600,509 shs
Market Capitalization: $5.04 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $78.78

Intra-Cellular Therapies MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 50.1% Upside
$78.78 Price Target
Short Interest: Healthy
2.32% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.23
Upright™ Environmental Score
News Sentiment: 1.29
Based on 6 Articles This Week
Insider Trading: Selling Shares
$6.36 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.08) to ($0.83) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.73 out of 5 stars

Medical Sector

95th out of 975 stocks

Pharmaceutical Preparations Industry

28th out of 448 stocks

3.5

Analyst's Opinion

Consensus Rating
Intra-Cellular Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $78.78, Intra-Cellular Therapies has a forecasted upside of 50.1% from its current price of $52.49.
Amount of Analyst Coverage
Intra-Cellular Therapies has only been the subject of 4 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.32% of the outstanding shares of Intra-Cellular Therapies have been sold short.
Short Interest Ratio / Days to Cover
Intra-Cellular Therapies has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Intra-Cellular Therapies has recently decreased by 12.55%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Intra-Cellular Therapies does not currently pay a dividend.
Dividend Growth
Intra-Cellular Therapies does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Intra-Cellular Therapies has received a 69.69% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is mostly driven by its "Antipsychotics", "Clinical research services for mood disorders", and "Clinical research services for substance abuse disorders " products. See details.
Environmental Sustainability
The Environmental Impact score for Intra-Cellular Therapies is -1.23.

3.5

News and Social Media Coverage

News Sentiment
Intra-Cellular Therapies has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Intra-Cellular Therapies this week, compared to 3 articles on an average week.
Search Interest
Only 1 people have searched for ITCI on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
2 people have added Intra-Cellular Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Intra-Cellular Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,359,174.00 in company stock.
Percentage Held by Insiders
Only 3.40% of the stock of Intra-Cellular Therapies is held by insiders.
Percentage Held by Institutions
86.94% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($2.08) to ($0.83) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Intra-Cellular Therapies is -27.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Intra-Cellular Therapies is -27.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Intra-Cellular Therapies has a P/B Ratio of 7.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Intra-Cellular Therapies (NASDAQ:ITCI) Stock

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

ITCI Price History

30 days | 90 days | 365 days | Advanced Chart

ITCI Stock News Headlines

October 3, 2023 | americanbankingnews.com

Short Interest in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Drops By 12.5%

September 27, 2023 | americanbankingnews.com

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives Average Rating of "Buy" from Analysts

October 3, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."

September 20, 2023 | finance.yahoo.com

Intra-Cellular Therapies to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

September 20, 2023 | gurufocus.com

Insider Sell: Sharon Mates Sells 100,000 Shares of Intra-Cellular Therapies Inc

September 11, 2023 | benzinga.com

Intra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed Features

September 5, 2023 | finance.yahoo.com

Loss-Making Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Expected To Breakeven In The Medium-Term

September 5, 2023 | finance.yahoo.com

Intra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

October 3, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

August 23, 2023 | msn.com

Cantor Fitzgerald Reiterates Intra-Cellular Therapies (ITCI) Overweight Recommendation

August 12, 2023 | seekingalpha.com

Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline

August 4, 2023 | finance.yahoo.com

Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance

August 3, 2023 | seekingalpha.com

Intra-Cellular Therapies Q2 2023 Earnings Preview

July 28, 2023 | finance.yahoo.com

Intra-Cellular Therapies to Host Second Quarter 2023 Financial Results Conference Call and Webcast

July 6, 2023 | markets.businessinsider.com

Needham Maintains Buy Rating for Intra-Cellular Therapies: Here's What You Need To Know

June 22, 2023 | markets.businessinsider.com

RBC Capital Sticks to Their Buy Rating for Intra-Cellular Therapies (ITCI)

June 20, 2023 | finance.yahoo.com

Drug Stock Poised For Growth With Record Sales, Strong Outlook

June 5, 2023 | finance.yahoo.com

ITCI Jul 2023 65.000 call

June 5, 2023 | msn.com

JP Morgan Maintains Intra-Cellular Therapies (ITCI) Overweight Recommendation

June 5, 2023 | markets.businessinsider.com

Analyst Expectations for Intra-Cellular Therapies's Future

June 5, 2023 | finance.yahoo.com

Intra-Cellular Therapies to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

May 31, 2023 | finance.yahoo.com

Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

May 31, 2023 | finance.yahoo.com

Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

May 8, 2023 | msn.com

Mizuho Maintains Intra-Cellular Therapies (ITCI) Buy Recommendation

May 8, 2023 | finance.yahoo.com

Investing in Intra-Cellular Therapies (NASDAQ:ITCI) three years ago would have delivered you a 208% gain

May 5, 2023 | msn.com

Cantor Fitzgerald Maintains Intra-Cellular Therapies (ITCI) Overweight Recommendation

May 5, 2023 | msn.com

RBC Capital Maintains Intra-Cellular Therapies (ITCI) Outperform Recommendation

See More Headlines

Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Company Calendar

Last Earnings: 8/03/2023
Today: 10/03/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ITCI
CUSIP: N/A
CIK: 1567514
Web: www.intracellulartherapies.com
Phone: (464) 440-9333
Fax: 646-440-9334
Employees: 561
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $78.78
High Stock Price Forecast: $98.00
Low Stock Price Forecast: $62.00
Forecasted Upside/Downside: +50.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.93)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-256,260,000.00
Net Margins: -50.40%
Pretax Margin: -50.36%
Return on Equity: -28.63%
Return on Assets: -24.81%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.58
Quick Ratio: 7.13

Sales & Book Value

Annual Sales: $364.16 million
Price / Sales: 13.83
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.93 per share
Price / Book: 7.57

Miscellaneous

Outstanding Shares: 95,926,000
Free Float: 92,665,000
Market Cap: $5.04 billion
Optionable: Optionable
Beta: 1.10

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Sharon Mates Ph.D. (Age 70)
Co-Founder, Chairman, CEO & Pres
Comp: $2.23M

Mr. Lawrence J. Hineline CPA (Age 67)
CPA, Sr. VP of Fin., CFO, Treasurer & Assistant Sec.
Comp: $820.53k

Mr. Michael I. Halstead J.D. (Age 50)
Exec. VP, Gen. Counsel & Sec.
Comp: $983.65k

Dr. Suresh K. Durgam M.D. (Age 54)
Exec. VP & Chief Medical Officer
Comp: $961.84k

Mr. Mark Neumann (Age 60)
EVP & Chief Commercial Officer
Comp: $998.36k

Dr. Robert E. Davis Ph.D. (Age 72)
Sr. VP & Chief Scientific Officer

Mr. Juan Fernando Sanchez (Age 52)
VP of Corp. Communications & Investor Relations

Ms. Karen Patruno Sheehy Esq. (Age 61)
Sr. VP & Chief Compliance Officer

Dr. Michael Olchaskey
Sr. VP & Head of Regulatory Affairs

Mr. John A. Bardi
Sr. VP of Market Access, Policy & Gov. Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ITCI Stock - Frequently Asked Questions

Should I buy or sell Intra-Cellular Therapies stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ITCI shares.
View ITCI analyst ratings or view top-rated stocks.
What is Intra-Cellular Therapies' stock price forecast for 2023?: 8 Wall Street analysts have issued 1-year price objectives for Intra-Cellular Therapies' stock. Their ITCI share price forecasts range from $62.00 to $98.00. On average, they expect the company's stock price to reach $78.78 in the next twelve months. This suggests a possible upside of 50.1% from the stock's current price.
View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts.
How have ITCI shares performed in 2023?: Intra-Cellular Therapies' stock was trading at $52.92 on January 1st, 2023. Since then, ITCI stock has decreased by 0.8% and is now trading at $52.49.
View the best growth stocks for 2023 here.
Are investors shorting Intra-Cellular Therapies?: Intra-Cellular Therapies saw a decline in short interest in September. As of September 15th, there was short interest totaling 2,230,000 shares, a decline of 12.5% from the August 31st total of 2,550,000 shares. Based on an average trading volume of 639,800 shares, the days-to-cover ratio is currently 3.5 days.
View Intra-Cellular Therapies' Short Interest.
When is Intra-Cellular Therapies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our ITCI earnings forecast.
How were Intra-Cellular Therapies' earnings last quarter?: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) released its quarterly earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.17. The biopharmaceutical company earned $110.80 million during the quarter, compared to the consensus estimate of $106.45 million. Intra-Cellular Therapies had a negative net margin of 50.40% and a negative trailing twelve-month return on equity of 28.63%. The business's revenue was up 99.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.92) earnings per share.

What ETFs hold Intra-Cellular Therapies' stock?: ETFs with the largest weight of Intra-Cellular Therapies (NASDAQ:ITCI) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares U.S. Pharmaceuticals ETF (IHE), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH).
What other stocks do shareholders of Intra-Cellular Therapies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).
What is Intra-Cellular Therapies' stock symbol?: Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."
How do I buy shares of Intra-Cellular Therapies?: Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Intra-Cellular Therapies' stock price today?: One share of ITCI stock can currently be purchased for approximately $52.49.
How much money does Intra-Cellular Therapies make?: Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $5.04 billion and generates $364.16 million in revenue each year. The biopharmaceutical company earns $-256,260,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.
How many employees does Intra-Cellular Therapies have?: The company employs 561 workers across the globe.
How can I contact Intra-Cellular Therapies?: Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for the company is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at ir@intracellulartherapies.com, or via fax at 646-440-9334.

This page (NASDAQ:ITCI) was last updated on 10/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial